Loading...
Market
What will be the market share of TECELRA® by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from reputable firms (e.g., Gartner, IDC)
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA® for Advanced Synovial Sarcoma
Aug 1, 2024, 06:03 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking it as the first approved engineered cell therapy for a solid tumor. This milestone approval extends the power of immunotherapies into difficult-to-reach sarcomas, specifically targeting advanced synovial sarcoma, a rare cancer that arises in the body's soft tissues. Adaptimmune's TECELRA® is also noted as a significant development in TCR gene therapy.
View original story
Similar markets
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%